Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 3
Author: Motilal Oswal

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	27 Jun 2025	Dr. Reddy's Labs	Consensus Share Price Target	1301.00	1268.74	-	-2.48	hold	pdf Detailed Estimates
	28 Oct 2023	Dr. Reddy's Labs	Motilal Oswal Target	1301.00	5400.00	5397.30 (-75.90%)	Target met	Neutral	pdf post cache	Broker Report Niche products lead to superior margins Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	28 Oct 2023	Dr. Reddy's Labs	ICICI Securities Limited	1301.00	6000.00	5397.30 (-75.90%)	Target met	Accumulate	pdf post cache	Broker Report Cost pressure dents margins ICICI Securities Limited Dr. Reddy’s Laboratories’ (DRL) Q2FY24 gross and EBITDA margins were down 198bps/273bps YoY to 58.7%/28.9%, respectively. US price erosion, acquisition of Mayne Pharma and higher SG&A investments dented margins. pdf Copy Link Share on Share on Share on Share on Alert
	24 Aug 2023	Dr. Reddy's Labs	Geojit BNP Paribas Reco Target	1301.00	6212.00	5907.15 (-77.98%)	Target met	Hold	pdf post cache	Broker Report DR. REDDY'S LABORATARIES Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2023	Dr. Reddy's Labs	KRChoksey Target	1301.00	6560.00	5583.00 (-76.70%)	Target met	Buy	pdf post cache	Broker Report Strong quarter; rebound in US prices & gRevlimid drives growth KRChoksey DRReddy’s consolidated revenue increased by 7% QoQ to INR 67,579 Mn (+35% YoY ). The company reported a YoY revenue growth, driven increase in North America generics sales, The North America generics revenue stood at USD 390 Mn. The growth in this region was mainly driven by growth in gRevlimid sales. pdf Copy Link Share on Share on Share on Share on Alert
	27 Jul 2023	Dr. Reddy's Labs	SMC online	1301.00		5507.00 (-76.38%)	Pre-Bonus/ Split	Results Update	pdf post cache	Broker Report Dr. Reddys Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	27 Jul 2023	Dr. Reddy's Labs	Motilal Oswal Target	1301.00	5240.00	5507.00 (-76.38%)	Target met	Neutral	pdf post cache	Broker Report Sharp off-take in NA/Russia drive earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	27 Jul 2023	Dr. Reddy's Labs	Axis Direct Target	1301.00	6000.00	5507.00 (-76.38%)	Target met	Hold	pdf post cache	Broker Report Result Update:Dr Reddys Labs Axis Direct We have HOLD on the stock pdf Copy Link Share on Share on Share on Share on Alert
	27 Jul 2023	Dr. Reddy's Labs	ICICI Securities Limited Reco Target	1301.00	6000.00	5475.65 (-76.24%)	Target met	Accumulate	pdf post cache	Broker Report Better volumes in US drives margins ICICI Securities Limited Dr. Reddy’s (DRL) delivered a strong beat in EBITDA and profit, driven by incremental sales from its base product portfolio and gRevlimid in the US. gRevlimid continues to lift overall margins; however, additional sales from products that are in shortage in the US improved base business margins in Q1FY24. pdf Copy Link Share on Share on Share on Share on Alert
	27 Jul 2023	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1301.00	5150.00	5507.00 (-76.38%)	Pre-Bonus/ Split	Sell	pdf post cache	Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	04 Jul 2023	Dr. Reddy's Labs	Sharekhan Target	1301.00	5963.00	5178.35 (-74.88%)	Target met	Buy	pdf post cache	Broker Report Dr Reddys Labs Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
more loading

27.55% Gain from 52W Low

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1343.25. The consensus estimate represents an upside of 3.25% from the last price of 1301. View 21 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Niche products lead to superior margins

Cost pressure dents margins

DR. REDDY'S LABORATARIES

Strong quarter; rebound in US prices & gRevlimid drives growth

Dr. Reddys Laboratories

Sharp off-take in NA/Russia drive earnings

Result Update:Dr Reddys Labs

Better volumes in US drives margins

DR REDDY'S LABS

Dr Reddys Labs

Advisor Screeners